Trevi Therapeutics reports that two late-breaking abstracts have been accepted for presentation at upcoming fall medical conferences.
The previously disclosed positive interim data from CANAL, a phase 2 trial for chronic cough in IPF, will be presented as an oral late-breaker abstract presentation at the European Respiratory Society (ERS) International Congress 2022 in Barcelona, Spain.
The previously disclosed positive topline data from PRISM, a phase 2b/3 trial in PN, will be presented as an oral late-breaker abstract presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy.
Trevi is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF).